Vir Biotechnology, Inc. · NASDAQ:VIR
Vir Biotechnology — Investor Presentation (May 2021)
19 slides from Vir Biotechnology's investor presentation, May 27, 2021
Slide 1: A World Without Infectious Disease
Vir Biotechnology, Inc. A WORLD WITHOUT INFECTIOUS DISEASE May 26, 2021 Exhibit 99.2
Slide 2: Legal disclaimers: Forward-Looking Statements
Legal disclaimers © 2021 Vir Biotechnology, Inc. Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the expected success, cost, and tim
Slide 3: Taking on the most serious infectious diseases
© 2021 Vir Biotechnology, Inc. Taking on the most serious infectious diseases Products and product candidates with demonstrated clinical impact Applying learnings to broad ID pipeline Potential significant near-term value drivers
Slide 4: Antibodies with clinical impact
mAB114*: approved for therapy; as effective as three-antibody cocktail from Regeneron1 Antibodies with clinical impact © 2021 Vir Biotechnology, Inc. Ebola Sotrovimab (VIR-7831): U.S. Emergency Use Authorization (EUA) and European Medicines Agency (EMA) positive opinion under Article 5(3); 85% reduc
Slide 5: Antibody engineering technologies
Antibody engineering technologies © 2021 Vir Biotechnology, Inc. XX2 vaccinal mutation LS mutation Sotrovimab VIR-3434 VIR-7832 VIR-2482 VIR-7832 VIR-3434 Licensed from Rockefeller University Increase potency Induce T cell protection Licensed from Xencor Extend half-life Increase tissue concentratio
Slide 6: Antibodies in R&D
Antibodies in R&D Based on preclinical data © 2021 Vir Biotechnology, Inc. RSV/MPV Malaria Other diseases Pan-coronavirus HIV MRSA Broad strain coverage Single antibody covers two related respiratory pathogens Blocks infection Potential for long-lasting prophylaxis C. Diff Dengue Let’s be ready for
Slide 7: Additional technology platforms
Additional technology platforms © 2021 Vir Biotechnology, Inc. siRNA Rights to Alnylam siRNA technology for a certain number of infectious diseases Includes ESC+ modification to reduce off-target activity and potentially increase safety CMV Vaccines (T cell) Systematic CRISPR screening Cellular targ
Slide 8: Vir clinical development pipeline
Disease Area Product Candidate Treatment/ Prophylaxis Pre-clinical Phase 1 Phase 2 Phase 3 Authorized Collaborator COVID-19 Sotrovimab* Treatment Sotrovimab + bamlanivimab Treatment Sotrovimab* Prophylaxis VIR-7832 Treatment HBV VIR-2218 Treatment VIR-2218 + PEG-IFN-⍺ Treatment VIR-3434 Treatment VI
Slide 9: COVID-19
Vir Biotechnology, Inc. COVID-19
Slide 10: Sotrovimab: Design principles and clinical data
* Sarbecoviruses. 1. Pinto D, et al. Nature. 2020;583:290–5; 2. Vir Biotechnology, Press release, 18 May 2020 (accessed November 13, 2020); 3. Hope, IAS 2019- HIV & HBV Cure Forum, Mexico City 4. Sotrovimab incorporates Xencor’s Xtend technology © 2021 Vir Biotechnology, Inc. Sotrovimab: Design prin
Slide 11: Sotrovimab: Active against variants in circulation
Sotrovimab: Active against variants in circulation SA, BR mutant and other E484K + UK and other N501Y mutant + Scottish mutant + Mink mutant + Columbus, NY CA mutant and other L452R Month & Year * GISAID (human spike protein seqs; <10% Xs; >1018 aa (80% full length) © 2021 Vir Biotechnology, Inc. As
Slide 12: Potential next-generation antibodies
Potential next-generation antibodies © 2021 Vir Biotechnology, Inc. RBM Antibodies VIR-7832 Two leading candidates Highly potent in preclinical studies Cover all tested variants in circulation Same epitope as sotrovimab Enhancements intended for additional potency and induction of T cell protection
Slide 13: Hepatitis B (HBV)
Vir Biotechnology, Inc. Hepatitis B (HBV)
Slide 14: Broad HBV functional cure portfolio
Broad HBV functional cure portfolio © 2021 Vir Biotechnology, Inc. VIR-2218 Potential Best-In-Class siRNA as “backbone” of therapy Substantial, Durable, and Dose Dependent Reduction of HBsAg through 36 weeks1 Ongoing / Planned Combination Trials Placebo, n=8 20 mg, n=3 50 mg, n=9 100 mg, n=6 200 mg,
Slide 15: Attractive properties of VIR-3434
5,000-fold more potent than HBIG in in vitro neutralization assays Attractive properties of Vir-3434 © 2021 Vir Biotechnology, Inc. Potent Alteration in Fc shown to increase potency and induce protective T cell responses in animal models XX2 No significant adverse events identified in healthy volunt
Slide 16: VIR-3434 Phase 1 clinical data
© 2021 Vir Biotechnology, Inc. VIR-3434 Phase 1 clinical data First blinded cohort of eight patients with HBsAg levels less than 1,000 IU/ml Two received placebo Six received a single 6 mg dose of VIR-3434 Six of eight patients achieved a mean reduction of 1.3 log10 IU/mL HBsAg by day eight, the day
Slide 17: Four abstracts accepted for EASL 2021
A Phase 1 study evaluating the neutralizing, vaccinal monoclonal antibody VIR-3434 in participants with chronic hepatitis B virus infection Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results Prelim
Slide 18: GSK collaboration 2.0
GSK collaboration 2.0 Expansion of original coronavirus collaboration to include: mAbs for influenza treatment and prevention (including an option on VIR-2482) Up to 3 mAbs for non-influenza infectious disease targets Functional genomics for respiratory targets $345m in upfront and equity investment
Slide 19: 2021 anticipated catalysts
© 2021 Vir Biotechnology, Inc. 2021 anticipated catalysts Sotrovimab (mAb) Phase 3 (Early Treatment, COMET-TAIL, IM) Start 2Q VIR-3434 (mAb) Phase 1 Data 2Q VIR-2218 (siRNA) + PEG-IFN-⍺ Phase 2 initial clinical data Data 2Q VIR-2218 (siRNA) Phase 2 one-year response durability Data 2Q 1H 2021 2H 202